Related references
Note: Only part of the references are listed.Contrasting Immunopathogenic and Therapeutic Roles of Granulocyte Colony-Stimulating Factor in Cancer
Annette J. Theron et al.
PHARMACEUTICALS (2020)
Heme detoxification by heme oxygenase-1 reinstates proliferative and immune balances upon genotoxic tissue injury
Andreas Hedblom et al.
CELL DEATH & DISEASE (2019)
RRX-001 Acts as a dual small Molecule Checkpoint Inhibitor by Downregulating CD47 on Cancer Cells and SIRP-α on Monocytes/Macrophages
Pedro Cabrales
TRANSLATIONAL ONCOLOGY (2019)
An update on sargramostim for treatment of acute radiation syndrome
V. K. Singh et al.
DRUGS OF TODAY (2018)
RRx-001 protects against cisplatin-induced toxicities
Bryan Oronsky et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2017)
The macrophage stimulating anti-cancer agent, RRx-001, protects against ischemia-reperfusion injury
Pedro Cabrales et al.
EXPERT REVIEW OF HEMATOLOGY (2017)
A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells
D. S. Das et al.
LEUKEMIA (2016)
Concurrent whole brain radiotherapy and RRx-001 for melanoma brain metastases
Michelle M. Kim et al.
NEURO-ONCOLOGY (2016)
RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets
Corey A. Carter et al.
CASE REPORTS IN ONCOLOGY (2016)
G-CSF and GM-CSF in Neutropenia
Hrishikesh M. Mehta et al.
JOURNAL OF IMMUNOLOGY (2015)
Nrf2 activity as a potential biomarker for the pan-epigenetic anticancer agent, RRx-001
Shoucheng Ning et al.
ONCOTARGET (2015)
Granulocyte colony-stimulating factor exacerbates hematopoietic stem cell injury after irradiation
Chengcheng Li et al.
CELL AND BIOSCIENCE (2015)
FILGRASTIM FOR THE TREATMENT OF HEMATOPOIETIC ACUTE RADIATION SYNDROME
A. M. Farese et al.
DRUGS OF TODAY (2015)
Radioprotective agents for radiation therapy: future trends
Roberta M. Johnke et al.
FUTURE ONCOLOGY (2014)
Recent advances in radiation oncology: intensity-modulated radiotherapy, a clinical perspective
Katsumasa Nakamura et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2014)
Effect of Amifostine in Head and Neck Cancer Patients Treated with Radiotherapy: A Systematic Review and Meta-Analysis Based on Randomized Controlled Trials
Jundong Gu et al.
PLOS ONE (2014)
Determination of Sample Sizes for Demonstrating Efficacy of Radiation Countermeasures
Ralph L. Kodell et al.
BIOMETRICS (2010)
Gamma-tocotrienol, a tocol antioxidant as a potent radioprotector
Sanchita P. Ghosh et al.
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY (2009)
Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients
D Rades et al.
RADIOTHERAPY AND ONCOLOGY (2004)
Palifermin for oral mucositis after intensive therapy for hematologic cancers
R Spielberger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Amifostine in clinical oncology: current use and future applications
MI Koukourakis
ANTI-CANCER DRUGS (2002)
Share Paper
